This Week’s Big Picture

Over the past few months, fertility law developments have been moving quickly. Compared with prior weeks, this week appeared quieter on the legislative front.

But “quiet” does not mean nothing is changing.

The most important development this week is a subtle shift in how the federal government is talking about “fertility” and “infertility treatment.” This change does not currently affect your right to receive IVF treatment at a private clinic, nor does it immediately impact surrogacy contracts or parentage proceedings. But it reflects a broader trend: policy discussions around IVF, assisted reproduction, and family formation may become more frequent — and more political — in the months ahead.

Below are the key developments to watch this week.

1.  Federal Update: Washington Is Changing How It Talks About Infertility Treatment

Around April 28, several media outlets reported that the U.S. Department of Health and Human Services, or HHS, issued new guidance for Title X family planning clinics. Title X is a federally funded program that helps low-income individuals access reproductive health services, including contraception, gynecological exams, and sexual health screenings.

The new guidance shifts part of the program’s focus away from traditional contraception and family planning services, and toward what the administration describes as “natural family planning” and “restorative reproductive medicine.”

Why does this matter for IVF patients?

“Restorative reproductive medicine” generally refers to a non-IVF approach to infertility care. It often emphasizes lifestyle changes, ovulation and hormone tracking, and natural-cycle interventions. Some of these tools may be reasonable as part of an infertility evaluation. However, fertility specialists have raised concerns that if this language is overemphasized at the policy level, patients may feel pressured to “try natural methods first” before moving forward with IVF or medication-assisted treatment.

For patients, the important point is this: IVF and medication-assisted fertility treatment are established, common, and well-studied medical options. Every family’s situation is different, and the right treatment path should be based on age, diagnosis, ovarian reserve, sperm factors, embryo factors, medical history, and family-building goals. Medical decisions should be made by patients and their physicians — not by political language.

What makes this moment somewhat confusing is that the federal government has publicly stated support for expanding IVF access, while some policy documents are placing more emphasis on natural family planning and restorative reproductive medicine. These messages do not fully align.

We are still waiting for the White House’s previously promised IVF policy report. That report may provide more clarity on how the administration intends to support IVF, and whether it will address insurance coverage, medication costs, clinic regulation, or other federal measures. As of this week, that report has not yet been released.

The reassuring part is that the current Title X guidance does not change private IVF clinic treatment plans. It also does not directly affect your insurance, contracts, or surrogacy legal documents. If you are receiving IVF treatment, pursuing egg freezing, storing embryos, or going through a surrogacy-related medical process at a private clinic, this change itself does not suddenly stop your process.

That said, if you have felt pressured during medical care to “try natural methods first,” or if you are unsure when it is appropriate to move forward with IVF, that is a fair question to raise directly with your physician. Patients have the right to understand the medical basis, success rates, time costs, and risks of different treatment options.

2. . Birth Rate Data: Why Fertility Policy Is Getting More Attention

Another important background development this week is the CDC’s provisional 2025 birth data. The data shows that the U.S. general fertility rate continued to decline, reaching its lowest level in more than a century. Teen birth rates also continued to fall.

This may seem unrelated to an individual fertility case, but it is part of the broader backdrop behind many recent fertility policy debates.

Why are more states discussing IVF insurance coverage? Why is the White House preparing an IVF policy report? Why is the federal government changing the language used in Title X guidance? Why are issues involving surrogacy, embryos, parentage, and birthright citizenship appearing more often in public debate?

A major reason is that the United States is facing a long-term decline in birth rates. Across party lines, policymakers are increasingly recognizing that fertility, family formation, and assisted reproduction are no longer only private matters. They are becoming public policy issues.

For patients and intended parents, this is a double-edged sword.

On the positive side, more attention may bring more support. IVF insurance coverage, employer fertility benefits, medication cost assistance, and protections for embryo storage may all move forward because of increased policy attention.

But the risk is that more attention may also bring more interference. Different states, political groups, and value systems may have very different answers to questions such as: which families should be supported, how embryos should be defined, and whether surrogacy should be restricted.

For families pursuing IVF, surrogacy, egg donation, embryo storage, or cross-state parentage arrangements, it is no longer enough to focus only on the medical process. The legal environment matters as well. This is especially true in cross-state arrangements, where families should confirm in advance: where the contract will be signed, which state’s law will apply, where parentage will be established, and which state will issue the birth certificate.

This Week’s Takeaway

This week did not bring many new laws, but several signals are worth watching closely.

The federal language shift around Title X reminds us that IVF and infertility treatment are entering a broader policy conversation. For now, it does not change the IVF process at private clinics, but it may influence how the government defines and supports “fertility treatment” in the future.

The continued decline in birth rates also helps explain why fertility policy is receiving more attention. In the coming months and years, we should expect more discussion around IVF, insurance coverage, surrogacy, embryos, and parentage.

Sometimes legal change does not appear suddenly on the day of delivery. It can begin much earlier — at the contract stage, during embryo transfer planning, or while parentage documents are being prepared. The earlier families confirm their legal path, the more opportunities they have to adjust.

For legal advice regarding your specific situation, please consult with an attorney.

This alert is for general information only and does not constitute legal advice. If you have questions about your specific situation, please speak with an attorney.